Anti-CD47 Reference Antibody (letaplimab) is a key tool in biopharmaceutical research and development, particularly in immunology and cancer therapy. It targets and blocks the CD47 protein on tumor cells, which acts as a "don't eat me" signal that allows cancer to evade the immune system. By inhibiting CD47, the antibody promotes phagocytosis by macrophages and other immune cells, enabling more effective recognition and destruction of cancer cells.

This reference antibody is used as a standard in preclinical studies, bioassays (e.g., binding assays, phagocytosis induction), and safety evaluations in animal models. It serves as a benchmark for comparing the efficacy of novel anti-CD47 antibodies. Letaplimab is investigated in clinical trials for hematologic malignancies such as leukemia, lymphoma, myelodysplastic syndromes, and acute myeloid leukemia, as well as solid tumors. It is often studied in combination with other monoclonal antibodies like rituximab or cetuximab, or chemotherapies, to enhance anti-tumor activity.

Additionally, it plays a role in quality control of biologic products, serving as a reference for assessing purity, stability, and bioactivity of commercially produced antibodies.